|
Sex: Male/Female
|
17/14
|
|
Age (years)
| |
|
Median
|
60
|
|
Range
|
24-81
|
|
WHO Performance status, n(%)
| |
|
0
|
10 (32)
|
|
1
|
16 (52)
|
|
2
|
4 (13)
|
|
3
|
1 (3)
|
|
Primary tumor location, n (%)
| |
|
Colon
|
23
|
|
Rectum
|
8
|
|
Metastatic sites, n (%)
| |
|
Liver
|
26 (84)
|
|
Lung
|
13 (42)
|
|
Peritoneum
|
5 (16)
|
|
Others
|
12 (39)
|
|
Number of metastatic sites, n (%)
| |
|
1
|
15 (48)
|
|
2
|
10 (32)
|
|
≥ 3
|
7 (23)
|
|
Chemotherapy associated with bevacizumab, n (%)
| |
|
FOLFIRI
|
19 (61)
|
|
FOLFOX4
|
12 (39)
|
|
Line number of bevacizumab, n (%)
| |
|
2nd line
|
1(3.25)
|
|
3rd line
|
10 (32.25)
|
|
4th line
|
10 (32.25)
|
|
5th or later-line
|
10 (32.25)
|
|
Previous chemotherapy
| |
|
Fluoropyrimidine + irinotecan + oxaliplatin
|
27
|
|
Fluoropyrimidine + irinotecan
|
3
|
|
Fluoropyrimidine + oxaliplatin
|
1
|
|
Cetuximab
|
19
|
